Drug combinations for the treatment of duchenne muscular dystrophy
Combinations comprising (or consisting essentially of) one or more compounds of formula (1) with one or more ancillary agents, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.
1. A combination comprising the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole and a corticosteroid.
2. The combination of claim 1 wherein the corticosteroid is selected from prednisone, prednisolone, and deflazacort.
3. The combination of claim 1 wherein the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole are physically associated; or the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole are non-physically associated; or the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole are
a) in admixture;
b) chemically/physicochemically linked;
c) chemically/physicochemically co-packaged; or
d) unmixed but co-packaged or co-presented.
4. The combination of claim 2 wherein the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole are physically associated; or the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole are non-physically associated; or the corticosteroid and the compound 5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzo[d]oxazole are
a) in admixture;
b) chemically/physicochemically linked;
c) chemically/physicochemically co-packaged; or
d) unmixed but co-packaged or co-presented.
5. A pharmaceutical pack, kit or patient pack comprising the combination of claim 1 .
6. A pharmaceutical pack, kit or patient pack comprising the combination of claim 2 .